Previous 10 | Next 10 |
NantKwest (NK) appointed healthcare industry veteran Richard Adcock as its CEO, effective immediately.Richard will assume the role of CEO from Dr. Patrick Soon-Shiong, who will become the board's executive chairman; Dr. Soon-Shiong remains the largest shareholder in NantKwest.M...
Experienced Six Sigma healthcare executive bolsters leadership team at key juncture; will work closely with Dr. Patrick Soon-Shiong who will serve as Executive Chairman NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today appo...
NantKwest announces initiation of second generation COVID-19 vaccine candidate. Protagonist Therapeutics receives orphan drug status for PTG-300. Genmab reports positive data from Phase 2 CASSIOPEIA study. For further details see: NantKwest COVID-19 Candidate, And Other ...
Privately-held ImmunityBio and NantKwest (NK) have commenced dosing in Phase 1 trial of hAd5-COVID-19, a COVID-19 vaccine candidate that targets the inner nucleocapsid and the outer spike protein, engineered to activate both T cells and antibodies against the coronavirus.The 35-subject t...
First patient receives ImmunityBio’s second-generation hAd5 COVID vaccine, delivering both outer S (spike) protein and inner N (nucleocapsid) leading to potential long-term T cell and antibody immunity to the SARS-CoV-2 virus ImmunityBio, a privately-held immunotherap...
SPI Energy (SPI) +56% on entering agreement with Shaanxi Tongjia Automobile.Anavex Life Sciences (AVXL) +36% after completing mid-stage study of lead drug in rare brain development disorder.Organogenesis Holdings (ORGO) +27% on Q3 preliminary results.Huttig Build...
The FDA has granted approval to NantKwest (NK), up 6% premarket and its collaborating partner ImmunityBio to commence a Phase I clinical trial of hAd5-COVID-19.The hAd5-COVID-19 is a first human adenovirus serotype 5 (hAd5) vaccine candidate that targets both the inne...
First human adenovirus (hAd5) vector vaccine candidate to deliver both outer spike (S) and inner nucleocapsid (N) antigens from SARS-CoV-2, offering potential long-term T cell and antibody immunity to the SARS-CoV-2 virus Second-generation adenoviral vector platform designed to ge...
Kiniksa reports positive results for mavrilimumab. Biogen announces CRISPR collaboration with Scribe Therapeutics. NantKwest reports augmenting its Phase 2 pancreatic cancer trial. For further details see: Kiniksa Reports Positive Results, And Other News: The Good, Bad A...
NantKwest (NK) and its collaborating partner ImmunityBio have announced to add a third cohort to ongoing Phase 2 immunotherapy trial for locally advanced or metastatic pancreatic cancer, and include patients who have failed all approved standards of care.The therapy includes co...
News, Short Squeeze, Breakout and More Instantly...
NantKwest Company Name:
NK Stock Symbol:
NASDAQ Market:
Imerys Enters Long-Term Partnership with TotalEnergies for Renewable Power at its Santa Barbara County Facility PR Newswire A TotalEnergies solar and battery storage solution to bring 130-year-old Lompoc industrial site into new era of sustainability and smart energy manag...
Creates Leading Immunotherapy and Cell Therapy Company ImmunityBio , Inc. and NantKwest , Inc. ( NASDAQ: NK ), today announced the completion of their previously announced 100% stock-for-stock merger. This follows the satisfaction of all customary closing conditi...
NantKwest, Inc . ( NASDAQ: NK ), a clinical-stage, natural killer cell-based therapeutics company, today announced that its stockholders approved by the required vote each of the proposals related to the pending merger of NantKwest and ImmunityBio, Inc. presented at the special ...